Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Terns Pharmaceuticals (TERN) Tax Provisions (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Tax Provisions readings, the most recent being $33000.0 for Q4 2025.

  • Quarterly Tax Provisions fell 17.5% to $33000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $231000.0 through Dec 2025, down 11.15% year-over-year, with the annual reading at $231000.0 for FY2025, 11.15% down from the prior year.
  • Tax Provisions hit $33000.0 in Q4 2025 for Terns Pharmaceuticals, down from $46000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $346000.0 in Q4 2021 and bottomed at $6000.0 in Q2 2022.
  • Average Tax Provisions over 5 years is $76300.0, with a median of $59000.0 recorded in 2023.
  • The largest annual shift saw Tax Provisions crashed 80.39% in 2021 before it skyrocketed 1100.0% in 2023.
  • Terns Pharmaceuticals' Tax Provisions stood at $346000.0 in 2021, then fell by 8.09% to $318000.0 in 2022, then tumbled by 78.62% to $68000.0 in 2023, then plummeted by 41.18% to $40000.0 in 2024, then decreased by 17.5% to $33000.0 in 2025.
  • Per Business Quant, the three most recent readings for TERN's Tax Provisions are $33000.0 (Q4 2025), $46000.0 (Q3 2025), and $64000.0 (Q2 2025).